Exact Sciences Corporation (NASDAQ:EXAS) shares are up 9% today after Anthem Blue Cross announced a positive coverage decision for Exact’s Cologuard test. Anthem is the largest …
In a research report published Friday, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) and raised the price target …
In a research report issued this morning, Canaccord Genuity analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $27 price …
Exact Sciences Corp. (NASDAQ:EXAS) announced that Aetna, one of the country’s leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 …
In a research report released today, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS), and reduced the price target to …
Canaccord Genuity’s healthcare analyst Mark Massaro weighed in today with a few insights on EXACT Sciences Corporation (NASDAQ:EXAS), after the stock plunged following the company’s fourth-quarter call. The …
Exact Sciences Corp. (Nasdaq:EXAS) announced its financial results for the quarter and year ended Dec.
(BUSINESS WIRE)– Exact Sciences Corp. (NASDAQ:EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and …
Roth Capital analyst Chris Lewis came out today with an update on Exact Sciences Corp (NASDAQ:EXAS), as the company is in the stage of commercialization of …
(BUSINESS WIRE)– Exact Sciences Corp. (Nasdaq:EXAS) today announced that during 2014 it completed and reported a diagnostic result for 4,024 Cologuard tests, more …
